

PDF issue: 2025-07-22

Cholelithiasis prevalence and risk factors in individuals with severe or profound intellectual and motor disabilities

Watanabe, Aya ; Tomioka, Yuichiro ; Okata, Yuichi ; Yoshimura, Shohei ; Kumode, Satoshi ; Iwabuchi, Serena ; Kameoka, Yasuyuki ; Takanarita,…

(Citation)

Journal of Intellectual Disability Research, 68(4):317-324

(Issue Date) 2024-01-06

(Resource Type) journal article

(Version) Accepted Manuscript

(Rights)

This is the peer reviewed version of the following article: Watanabe, A., Tomioka, Y., Okata, Y., Yoshimura, S., Kumode, S., Iwabuchi, S., Kameoka, Y., Takanarita, Y., Uemura, K., Samejima, Y., Kawasaki, Y., and Bitoh, Y. (2024) Cholelithiasis prevalence and risk factors in individuals with severe or profound intellectual and motor…

(URL)

https://hdl.handle.net/20.500.14094/0100491871



Cholelithiasis Prevalence and Risk Factors in Individuals with Severe or Profound Intellectual and Motor Disabilities

Aya Watanabe¹, Yuichiro Tomioka¹, Yuichi Okata^{1*}, Shohei Yoshimura¹, Satoshi Kumode¹, Serena Iwabuchi¹, Yasuyuki Kameoka¹, Yuki Takanarita¹, Kotaro Uemura¹, Yoshitomo Samejima¹, Yoko Kawasaki², Yuko Bitoh¹

¹Division of Pediatric Surgery, Department of Surgery, Kobe University Graduate School of Medicine, Kobe, Japan ²Nikoniko House Kobe Medical and Welfare Center, Kobe, Japan **Aya Watanabe and Yuichiro Tomioka contributed equally to this work.**

*Corresponding Author: Yuichi Okata M.D., Ph.D.

Division of Pediatric Surgery, Department of Surgery, Kobe University Graduate School of Medicine, Kobe, Japan E-mail: yuichi.okata@gmail.com Telephone: +81-78-382-5943, Fax: +81-78-382-5942

Acknowledgments

We would like to thank Editage (www.editage.com) for English language editing.

Funding

All authors have not received any specific grant from funding agencies in the public,

commercial, or not-for-

profit sectors.

Conflict of interest disclosure

The authors do not have a conflict of interest to report.

Data availability statement

Data are available upon request from the corresponding author

Ethics approval statement (for studies involving animal subjects and/or human participants)

This study was approved by the local Institutional Review Board (B220051).

Permission to reproduce material from other sources

No material requiring permissions has been reproduced in this manuscript.

Cholelithiasis Prevalence and Risk Factors in Individuals with Severe or Profound Intellectual and Motor Disabilities

3

4 Abstract

Background: The prevalence and risk factors of cholelithiasis in individuals with severe or
profound intellectual and motor disabilities (SPIMD) are poorly characterised. Thus, we
aimed to investigate the prevalence and risk determinants of cholelithiasis in a cohort with
SPIMD under medical care in a residential facility.

9 Method: We categorised 84 patients in a residential hospital for persons with SPIMD into

10 groups: those with (Group CL) and without (Group N) cholelithiasis. Gallstones were

11 detected via computed tomography, ultrasonography, or both. We evaluated gastrostomy

12 status, nutritional and respiratory support, constipation, and bladder and kidney stones. Data

13 were significantly analysed using univariate and multivariate logistic regression analyses.

14 **Results:** The prevalence rate of cholelithiasis in our SPIMD cohort was 27%. Sex, age,

15 weight, height, or Gross Motor Function Classification System scores between the groups.

16 However, more patients received enteral nutrition (39.13% vs. 6.56%, P = .000751) and were

17 on ventilator support (56.52% vs. 19.67%, P = .00249) in Group CL than in Group N. Enteral

18 nutrition (odds ratio [OR] 10.4, 95% confidence interval [CI] 1.98–54.7) and ventilator

19 support (OR 20.0, 95% CI 1.99–201.0) were identified as independent risk factors for the

20 prevalence of cholelithiasis in patients with SPIMD.

Conclusions: Patients with SPIMD demonstrated an increased prevalence of cholelithiasis,
with a notable association between nutritional tonic use and respiratory support. Therefore, to
emphasise the need for proactive screening, it is crucial to devise diagnostic and therapeutic
strategies specific to patients with SPIMD. Further investigation is essential to validate our
findings and explore causative factors.

- 27 Keywords: gallstones; severe or profound intellectual and motor disabilities; prevalence; risk
- 28 factor

30 Background

31 Cholelithiasis is a significant health issue with well-established risk factors, such as obesity, rapid weight loss, dietary habits, age, sex, familial background, ethnicity, and certain diseases 32 33 in the general population, including diabetes and cirrhosis (Fujita et al. 2023, Amorim-Cruz 34 et al. 2023, Song et al. 2020, Littlefield and Lenahan 2019, Di Ciaula et al. 2019, Mayumi et 35 al. 2018, Zhang et al. 2017, Pak and Lindseth 2016, Lammert et al. 2016, Wong and Ko 36 2013, Kitamura and Ogino 2011, Sanders and Kingsnorth 2007, Shaffer 2006, Halldestam et 37 al. 2004). The estimated prevalence of cholelithiasis varies geographically and with populations. For example, the prevalence of gallstones is 14%-20% in Europe and the USA, 38 39 but lower in East Asia, particularly in Japan, where it is 4%–10% (Unalp-Arida et al. 2023, Ferkingstad et al. 2018, Higashizono et al. 2022, Fujita et al. 2021, Index of Health 1993). 40 41 The global prevalence of cholelithiasis among children aged <18 years has increased to 1.9%–4%. This might be linked to an increased rate of childhood obesity as well as dietary 42 43 factors and the extensive use of ultrasound for diagnostic purposes (Jeanty et al. 2015, Parra-44 Landazury et al. 2021, Krawczyk et al. 2023, Zdanowicz et al. 2022, Fujita et al. 2021). 45 However, the specific prevalence and risk factors of cholelithiasis in individuals with severe or profound intellectual and motor disabilities (SPIMD) defined as a combination of severe 46 47 physical disability and severe mental retardation due to conditions including cerebral palsy 48 (CP) and neuromuscular disorders, are largely unknown (Zuo et al. 2022, van Timmeren et al. 49 2017).

Patients with SPIMD have a high incidence of gastrointestinal disorders and respiratoryrelated complications, such as pneumonia, and are particularly prone to severe and prolonged
infections that require a more detailed diagnosis and treatment (van Timmeren et al. 2016,
Hermans and Evenhuis 2014, van Schrojenstein Lantman-de Valk and Walsh 2008).
Additionally, patients with SPIMD are prone to multiple comorbidities that complicate their

condition (van Timmeren et al. 2016). Therefore, each disease needs to be detected early to
ensure appropriate intervention.

57 Cholelithiasis is a potential disease for patients with SPIMD but may be difficult to 58 accurately diagnose due to physical abnormalities such as scoliosis and a limited ability to 59 clearly express or understand physical symptoms (Zuo et al. 2022). Furthermore, 60 implementing appropriate surgical or endoscopic treatment is difficult because of the risk of 61 complications associated with sedation, general anaesthesia, or physical abnormalities such as 62 severe scoliosis (Khalid and Al-Salamah 2006). Therefore, there is an urgent need to clarify the epidemiology and risk factors of cholelithiasis in patients with SPIMD to prevent the 63 64 disease and assist in early detection. However, to the best of our knowledge, only one study has focused on patients with SPIMD (Zuo et al. 2022). Thus, we aimed to determine the 65 66 prevalence of cholelithiasis in this unique population, identify risk factors, and assess the prevalence of symptoms and complications among patients with severe mental and physical 67 68 disabilities residing in welfare facilities.

69

70 Methods

We retrospectively reviewed charts of patients from the Niko Niko House Medical Welfare Center, which is a residential facility that provides full-time care exclusively for persons with SPIMD resulting from diverse aetiologies. These include congenital conditions such as CP, as well as acquired infections and neurological disorders. The prevalence of gallstones was determined from medical records collected between 1 January 2020 and 1 January 2021 to better understand variations in gallstone diagnoses. Charts with insufficient medical record data were excluded.

Diagnoses of cholelithiasis were determined from a combination of CT and ultrasound
 examinations, which are more sensitive and specific for gallstone detection, between 1

80 January 2020 and 31 December 2020. This approach enhanced the accuracy of our 81 prevalence data (Fujita et al. 2023, Mayumi et al. 2018, Lammert et al. 2016). Data from 84 82 residents (median age, 42.5 [5–76] years) were included and assigned to Group CL (n = 23; 83 27%) and Group N (n = 61; 73%). We assigned the residents to groups with (CL) and without 84 (N) cholelithiasis to investigate potential risk factors. Individuals presenting solely with 85 biliary sludge were included in Group N. We analysed the following established factors that have been validated by similar studies: 86 87 body mass index (BMI); Gross Motor Function Classification System (GMFCS) data; 88 presence of epilepsy, minimal communication skills (van Timmeren et al. 2017), cardiac 89 disease, diabetes, constipation (defined as the use of an enema at least once a day), bladder 90 stones, kidney stones; and history of gastrostomy, fundoplication for gastroesophageal reflux, 91 nutritional support, and respiratory support (tracheostomy, ventilator management, or non-92 invasive positive pressure ventilation) (Fujita et al. 2023, Amorim-Cruz et al. 2023, Pak et al. 93 2016). Oral intake was defined as the intake of food or beverages at least once a day, 94 regardless of the form, amount, or frequency, with or without enteral nutrition use, total 95 caloric intake (defined as daily caloric intake), and total fluid intake (defined as daily fluid 96 intake).

97 This study was approved by the ethics review committee of the institution (protocol no.
98 B210086). Written informed consent was obtained from parents., family members, or
99 guardians.

100

101 Statistical analysis

Continuous variables are presented as mean ± standard deviation and were compared using
 the Mann–Whitney U test. Categorical data were analysed using Fisher's exact tests. The risk
 factors for cholelithiasis in patients with SPIMD were analysed using univariate logistic

105 regression to derive odds ratios (ORs) and corresponding 95% confidence intervals (CIs).

106 Variables with p < .05 in univariate analysis were included in multivariate models.

107 All statistical analyses were performed using EZR software (Saitama Medical Center, Jichi

108 Medical University, Saitama, Japan), a modified version of R Commander (version 1.55)

109 customised for biostatistics. Differences were considered statistically significant at p < .05.

110

111 **Results**

112 Patient demographics and clinical characteristics are shown in Table 1. The prevalence of 113 cholelithiasis in our SPIMD cohort was 27%. One and four patients in Groups CL and N were aged <18 years, among whom 1 (20%) in Group CL had gallstones. The causes of 114 115 SPIMD in the study population comprised neuromuscular diseases (n = 33), CP (n = 23), 116 hypoxic encephalopathy (n = 14), and infections (n = 7). One patient in Group CL had 117Herpes encephalitis (n = 1). Group N contained one patient each with congenital 118 Cytomegalovirus infection, and sequelae of purulent meningitis, measles encephalitis, and 119 Japanese encephalitis; two had congenital Rubella syndrome (n = 2); and seven had 120 chromosomal abnormalities. The causes of SPIMD did not significantly differ between the 121 two groups. All patients underwent abdominal ultrasonography, abdominal CT, or both. Demographic parameters such as mean age $(43.57 \pm 15.62 \text{ vs.} 42.64 \pm 15.82 \text{ years; } p = .80)$, 122 mean weight $(39.51 \pm 8.04 \text{ vs.} 36.78 \pm 9.35 \text{ kg}; \text{p} = .2)$, mean height $(153.79 \pm 12.46 \text{ vs.}$ 123 149.61 ± 15.52 cm; p = .25), and mean BMI (16.69 ± 2.71 vs. 16.41 ± 3.83 kg/m²; p = .75) 124125 did not significantly differ between the groups even when accounting for patients with a BMI of >25 kg/m² (classified as obese). Sex distribution between the groups (19 males and 4 126 127 females in Group CL vs. 37 males and 24 females in Group N) also did not significantly differ (p = .072). 128

129 Epilepsy was a prevalent comorbidity that did not significantly differ between Groups CL

130	and N (n = 20 [86.96%] vs. 52 [85.3%]), (p = 1.0). Other comorbidities, such as impaired
131	communication (p =.20), cardiac disease (p = 1.0), diabetes (p = .48), bladder stones (p
132	= .60), and urinary stones (p=.50), also did not significantly different. However, there was a
133	significant difference was observed in tracheostomy/laryngotracheal separation (p=.024) and
134	ventilator support (p=.0025), both of which were significantly higher in Group CL than in
135	Group N. Furthermore, patients in Group CL had a significantly higher reliance on enteral
136	nutrition than those in Group N (39.1% vs. 6.56%; $p = .00075$).
137	Regarding gastrostomy and fundoplication procedures, no significant differences were found
138	between the groups (n = 13 vs. 20, p = .34; and 21.7% vs. 24.6%, p = 1.0, respectively).
139	Constipation was equally prevalent in both groups (78.3% in Group CL vs. 80.3% in Group
140	N; p=1.0). Total calorie intake per weight and total water intake per weight did not differ
141	significantly between the groups (28.82 \pm 7.59 vs. 32.99 \pm 10.91; p = .096 and 33.43 \pm 15.72
142	vs. 31.07 ± 13.34 ; p = .49, respectively). Biliary inflammatory diseases, such as cholecystitis
143	and cholangitis developed in 6 (26%) of 23 residents in Group CL with a mean age of 41.1
144	(16-68) years. These residents had clinical symptoms of fever and an increased heart rate, but
145	no abdominal tenderness, recurrent pain, general malaise, or visible jaundice. Cholecystitis
146	and cholangitis were suspected based on elevated biliary enzymes and blood levels of
147	inflammatory markers. The diagnosis was confirmed based on findings of ultrasonography
148	and other imaging modalities. Cholecystitis in all six affected patients was severe enough to
149	require cholecystectomy, and two of them also required preoperative endoscopic retrograde
150	cholangiopancreatography (ERCP) or percutaneous transhepatic gallbladder drainage
151	(PTGBD). The severity of cholecystitis was confirmed during surgery. Only 1 of the 61
152	patients in Group N developed biliary inflammatory disease, presenting with fever and
153	tachycardia. This patient's condition improved with conservative treatment, and
154	cholecystectomy was avoided.

156 Multivariate analyses of the prevalence of cholelithiasis in residents with SPIMD

- 157 Results of multivariate logistic regression analysis demonstrated that the risk factors for the
- 158 prevalence of cholelithiasis in patients with SPIMD were enteral nutrition (OR 10.4, 95% CI
- 159 1.98–54.7) and ventilator support (OR 20.0, 95% CI 1.99–201.0).
- 160 Tracheostomy/laryngotracheal separation was not significant after adjustment for ventilator
 161 support (OR 0.16, 95% CI 0.014–1.82) (Table 2).

162

163 **Discussion**

We investigated the prevalence of cholelithiasis and risk factors in a cohort of residents at a facility that specifically provides care for patients with SPIMD. We found a high prevalence of cholelithiasis and identified the key risk factors, i.e., enteral nutrition, and ventilator support. This emphasised the need for proactive screening and specialised care for this

168 population and calls for more research to understand the underlying causes.

169 The prevalence of cholelithiasis in our cohort of SPIMD is 27%, which surpassed that of

170 4%–10% found in Japanese cohorts without SPIMD (Higashizono et al. 2022, Fujita et al.

171 2021, Index of Health 1993). The incidence of acute cholecystitis or cholangitis in patients

172 with SPIMD accompanied by cholelithiasis is 25%, which is significantly higher than the

173 general incidence of cholelithiasis in patients with acute cholecystitis or cholangitis (1%–2%)

174 (Fujita et al. 2023, Littlefield and Lenahan 2019, Mayumi et al. 2018, Lammert et al. 2016).

175 These results emphasise the need for increased vigilance in the management of patients with

176 SPIMD for cholelithiasis and gallstone-related symptoms.

177 In this study, sex, age, weight, height, and GMFCS scores did not significantly differ

between patients with and without cholelithiasis. The lack of an association between these

179 factors and cholelithiasis in our SPIMD cohort contradicted findings of the general

180 population, where age, sex, and obesity are established important risk factors (Fujita et al. 181 2023, Amorim-Cruz et al. 2023, Song et al. 2020, Littlefield and Lenahan 2019, Di Ciaula et 182 al. 2019, Mayumi et al. 2018, Zhang et al. 2017, Pak and Lindseth 2016, Lammert et al. 2016, 183 Wong and Ko 2013, Kitamura and Ogino 2011, Sanders and Kingsnorth 2007, Shaffer 2006, 184 Halldestam et al. 2004). This discrepancy might be due to a specific pathophysiological 185 mechanism in the SPIMD population or the result of the small sample size. Further studies 186 with larger cohorts are required to clarify whether sex, age, weight, height, and GMFCS 187 scores or age, sex, and obesity are risk factors that also apply to patients with SPIMD. 188 The frequency of dietary supplement intake at least once a day significantly differed 189 between the groups. This suggested that supplements play roles in gallstone formation. 190 Enteral nutritional supplements, which often contain carbohydrates with a high glycaemic 191 index, may contribute to gallstone formation via a hyperinsulinaemic mechanism (Wong and 192 Ko 2013). Serum sphingolipids are potential biomarkers of cholelithiasis in children 193 (Zdanowicz et al. 2022). This biomarker might be useful as an early diagnostic tool for 194 SPIMD populations because nutritional supplements for patients with SPIMD contain 195 ingredients derived from milk and soy that are rich in sphingolipids. Increased contents of 196 specific sphingolipids might also elevate the risk of gallstone formation. Therefore, patients with SPIMD using nutritional supplements might be at a higher risk of developing gallstones 197 198 (Zdanowicz et al. 2022). Regarding enteral nutrition, gastrostomy and fundoplication did not 199 significantly correlate between the groups. However, vagal nerve damage due to 200 fundoplication is involved in gallstone formation (Sallum et al. 2015, Stahlgren et al. 1980), 201 and further investigation is warranted. No significant association was found between 202 constipation and its management in the present study. Despite these findings, the exact 203 underlying mechanism and relationship between enteral nutrition and gallstone formation 204 remain unclear, and further studies are essential to validate and elucidate the potential

205 mechanisms.

206 In patients with SPIMD, a history of tracheostomy or laryngotracheal separation and the need for respiratory assistance, especially mechanical ventilation, are associated with a higher 207 208 risk of gallstone formation. This is consistent with previous findings of a higher incidence of 209 cholelithiasis and cholecystitis in patients with SPIMD who are dependent on invasive 210 ventilation through long-term tracheostomy (Kitamura and Ogino 2011). However, the close 211 correlation between tracheostomy and respiratory assistance, such as laryngotracheal 212 isolation and mechanical ventilation, and possible correlations with other risk factors, such as 213 prolonged bed rest might be significant confounding factors. These factors interfered with our 214 ability to identify precise mechanistic associations between respiratory support and gallstone 215 formation. 216 In severe cases of acute cholecystitis, various therapeutic approaches, such as PTGBD, were 217 necessary. The high degree of inflammation encountered during cholecystectomy increases 218 the complexity of routine surgical procedures and prolongs the surgical duration. This 219 highlights the complications and severity associated with gallbladder disease. 220 We evaluated 6 (25%) of 24 patients with acute cholecystitis that was treated by 221 cholecystectomy. The age at the onset of acute cholecystitis was 41.1 years, which is younger 222 than the average age at onset in the general population (50–60 years) (Fujita et al. 2023, 223 Amorim-Cruz et al. 2023, Song et al. 2020, Littlefield and Lenahan 2019). The details of 224 these patients could not be obtained from medical records. A 54-year-old female with 225 detailed information was diagnosed late because of a lack of symptoms other than fever and 226 required PTGBD before cholecystectomy and endoscopic retrograde 227 cholangiopancreatography at a later date due to severe cholecystitis, requiring more than 2 228 months of hospitalisation. 229 The period between the onset of acute cholecystitis and the start of treatment is an important

factor that influences patient outcomes. Considering the higher prevalence of cholelithiasis and acute cholecystitis in patients with SPIMD than in the general population, early detection and timely intervention are important to prevent the progression of acute cholecystitis to lifethreatening sepsis (Fujita et al. 2023, Amorim-Cruz et al. 2023, Song et al. 2020, Littlefield and Lenahan 2019). Therefore, regular and proactive monitoring of these patients for early signs and symptoms is essential to enable timely intervention and optimise their clinical outcomes.

237 This study has some limitations. First, this was an observational study conducted at a single 238 institution, which could introduce potential selection bias. Additionally, our conclusions were 239 based on a small number of patients, underscoring the need for further investigations to 240 establish definitive relationships between the diagnostic difficulty or severity of acute 241 cholecystitis and the necessity for cholecystectomy. The retrospective nature of this study 242 also warranted consideration, and the presence of missing data, such as information regarding the type of cholelithiasis and treatment specifics, could have influenced the outcomes. To 243 244 gain a more comprehensive understanding of the risk and pivotal factors for cholelithiasis in 245 SPIMD populations, future prospective and broad-ranging studies should provide clearer 246 insights into the subject matter.

In conclusion, we found a higher prevalence of cholelithiasis and incidence of acute 247 248 cholecystitis in persons with SPIMD than in the general population and that ventilator 249 support and use of enteral nutrition were risk factors for cholelithiasis in patients with 250 SPIMD. We believe that this comprehensive understanding of the prevalence and risk factors 251 for cholelithiasis in patients with SPIMD may contribute to the development of prevention 252 strategies and therapeutic interventions for cholelithiasis in such patients. These findings have clinical implications that may require further investigations in larger cohorts to advance our 253 254 understanding of the pathophysiology of SPIMD.

References

256	Amorim-Cruz, F., Santos-Sousa, H., Ribeiro, M., Nogueiro, J., Pereira, A., Resende, F., et al.
257	(2023) Risk and prophylactic management of gallstone disease in bariatric surgery: a
258	systematic review and a Bayesian meta-analysis. Journal of Gastrointestinal Surgery 27, 433-
259	48. <u>https://doi.org/10.1007/s11605-022-05567-8</u> .
260	
261	Di Ciaula, A., Garruti, G., Frühbeck, G., De Angelis, M., de Bari, O., Wang, D.Q., et al.
262	(2019) The role of diet in the pathogenesis of cholesterol gallstones. Current Medicinal
263	Chemistry 26, 3620-38. https://doi.org/10.2174/0929867324666170530080636.
264	
265	Ferkingstad, E., Oddsson, A., Gretarsdottir, S., Benonisdottir, S., Thorleifsson, G., Deaton,
266	A.M., et al. (2018) Genome-wide association meta-analysis yields 20 loci associated with
267	gallstone disease. Nature Communications 9, 5101. https://www.nature.com/articles/s41467-
268	018-07460-у
269	
270	Fujita, N., Yasuda, I., Endo, I., Isayama, H., Iwashita, T., Ueki, T., et al. (2023) Evidence-
271	based clinical practice guidelines for cholelithiasis 2021. Journal of Gastroenterology 58,
272	801-33. https://doi.org/10.1007/s00535-023-02014-6.
273	
274	Halldestam, I., Enell, E.L., Kullman, E. & Borch, K. (2004) Development of symptoms and
275	complications in individuals with asymptomatic gallstones. British Journal of Surgery 91, 734-
276	8. <u>https://doi.org/10.1002/bjs.4547</u> .
277	
278	Higashizono, K., Nakatani, E., Hawke, P., Fujimoto, S. & Oba, N. (2022) Risk factors for
279	gallstone disease onset in Japan: Findings from the Shizuoka Study, a population-based

280 cohort study. PLoS One 17, e0274659. https://doi.org/10.1371/journal.pone.0274659.

281

- Jeanty, C., Derderian, S.C., Courtier, J. & Hirose, S. (2015) Clinical management of infantile
 cholelithiasis. Journal of Pediatric Surgery 50, 1289-92.
- 284 https://doi.org/10.1016/j.jpedsurg.2014.10.051.

285

- 286 Krawczyk, M., Kułaga, Z., Niewiadomska, O., Jankowska, I., Lebensztejn, D., Więcek, S., et
- al. (2023) Are children with gallstone disease more overweight? Results of a matched case-
- control analysis. Clinics and Research in Hepatology and Gastroenterology 47, 102204.
- 289 https://doi.org/10.1016/j.clinre.2023.102204.

- 291 Hermans, H. & Evenhuis, H.M. (2014) Multimorbidity in older adults with intellectual
- disabilities. Research in Developmental Disabilities 35, 776-83.
- 293 <u>https://doi.org/10.1016/j.ridd.2014.01.022</u>.
- 294
- 295 Khalid, K. & Al-Salamah, S.M. (2006) Surgery for acute abdominal conditions in
- intellectually-disabled adults. ANZ Journal of Surgery 76, 145-8.
- 297 <u>https://doi.org/10.1111/j.1445-2197.2006.03621.x</u>.
- 298
- 299 Kitamura, E. & Ogino, M. (2011) Occurrence of cholelithiasis and cholecystitis in
- 300 amyotrophic lateral sclerosis patients with long-term tracheostomy invasive ventilation.
- 301 Internal Medicine (Tokyo, Japan) 50, 2291-5.
- 302 <u>https://doi.org/10.2169/internalmedicine.50.5663</u>.
- 303
- 304 Lammert, F., Gurusamy, K., Ko, C.W., Miquel, J.F., Méndez-Sánchez, N., Portincasa, P., et

- al. (2016) Gallstones. Nature Reviews. Disease Primers 2, 16024.
- 306 <u>https://doi.org/10.1038/nrdp.2016.24</u>.
- 307
- 308 Littlefield, A. & Lenahan, C. (2019) Cholelithiasis: presentation and management. Journal of
- 309 Midwifery and Women's Health 64, 289-97. <u>https://doi.org/10.1111/jmwh.12959</u>.
- 310
- 311 Mayumi, T., Okamoto, K., Takada, T., Strasberg, S.M., Solomkin, J.S., Schlossberg, D., et al.
- 312 (2018) Tokyo Guidelines 2018: management bundles for acute cholangitis and cholecystitis.
- Journal of Hepato-Biliary-Pancreatic Sciences 25, 96-100. <u>https://doi.org/10.1002/jhbp.519</u>.
- 314
- 315 Parra-Landazury, N.M., Cordova-Gallardo, J., Méndez-Sánchez, N. (2021) Obesity and
- 316 Gallstones. Visc. Med 37, 394–402. https://doi.org/10.1159/000515545.
- 317
- 318 Pak, M. & Lindseth, G. (2016) Risk factors for cholelithiasis. Gastroenterology Nursing 39,
- 319 297-309. <u>https://doi.org/10.1097/SGA.0000000000235</u>.
- 320
- 321 Sallum, R.A., Padrão, E.M., Szachnowicz, S., Seguro, F.C., Bianchi, E.T. & Cecconello, I.
- 322 (2015) Prevalence of gallstones in 1,229 patients submitted to surgical laparoscopic treatment
- 323 of GERD and esophageal achalasia: associated cholecystectomy was a safe procedure.
- 324 Arquivos Brasileiros de Cirurgia Digestiva 28, 113-6. <u>https://doi.org/10.1590/S0102-</u>
- 325 <u>67202015000200007</u>.
- 326
- 327 Sanders, G. & Kingsnorth, A.N. (2007) Gallstones. BMJ 335, 295-9.
 328 <u>https://doi.org/10.1136/bmj.39267.452257.AD</u>.
- 329

- 330 Schans, C.P. (2017) Patterns of multimorbidity in people with severe or profound intellectual
 and motor disabilities. Research in Developmental Disabilities 67, 28-33.
- 332 <u>https://doi.org/10.1016/j.ridd.2017.05.002</u>.
- 333
- Shaffer, E.A. (2006) Gallstone disease: epidemiology of gallbladder stone disease. Best
 Practice & Research. Clinical Gastroenterology 20, 981-96.
 <u>https://doi.org/10.1016/j.bpg.2006.05.004</u>.
- 337
- 338 Song, S.T., Shi, J., Wang, X.H., Guo, Y.B., Hu, P.F., Zhu, F., et al. (2020) Prevalence and
- 339 risk factors for gallstone disease: a population-based cross-sectional study. Journal of
- 340 Digestive Diseases 21, 237-45. <u>https://doi.org/10.1111/1751-2980.12857</u>.
- 341
- Stahlgren, L.H., Pagana, T.J. & Costantino, G.N. (1980) Fundoplication for major reflux in
 patients with gallstones. Surgery, Gynecology and Obstetrics 150, 875-7.
- 344
- 345 Unalp-Arida, A., Der, J.S. & Ruhl, C.E. (2023) Longitudinal Study of Comorbidities and
- 346 Clinical Outcomes in Persons with Gallstone Disease Using Electronic Health Records.
- Journal of Gastrointestinal Surgery 1-4. https://doi.org/10.1007/s11605-023-05861-z.
- 348
- van Timmeren, E.A., van der Putten, A.A., van Schrojenstein Lantman-de Valk, H.M., van
 der Schans, C.P. & Waninge, A. (2016) Prevalence of reported physical health problems in
 people with severe or profound intellectual and motor disabilities: a cross-sectional study of
- 352 medical records and care plans. Journal of Intellectual Disability Research 60, 1109-18.
- 353 <u>https://doi.org/10.1111/jir.12298</u>.
- 354

355	van Timmeren, E.A., Waninge, A., van Schrojenstein Lantman-de, H.M.J., van der Putten,
356	A.A.J. & van der Schans, C.P. (2017) Patterns of multimorbidity in people with severe or
357	profound intellectual and motor disabilities. Research in Developmental Disabilities 67, 28-
358	33. <u>https://doi.org/10.1016/j.ridd.2017.05.002</u> .
359	
360	van Timmeren, E.A., Waninge, A., van Schrojenstein Lantman-de, H.M.J., van der Putten,
361	A.A.J. & van der van Schrojenstein Lantman-de Valk, H.M. & Walsh, P.N. (2008) Managing
362	health problems in people with intellectual disabilities. BMJ 337, a2507.
363	https://doi.org/10.1136/bmj.a2507.
364	
365	Wong, A.C. & Ko, C.W. (2013) Carbohydrate intake as a risk factor for biliary sludge and
366	stones during pregnancy. Journal of Clinical Gastroenterology 47, 700-5.
367	https://doi.org/10.1097/MCG.0b013e318286fdb0.
368	
369	Zdanowicz, K., Bobrus-Chcociej, A., Pogodzinska, K., Blachnio-Zabielska, A., Zelazowska-
370	Rutkowska, B., Lebensztejn, D.M., et al. (2022) Analysis of Sphingolipids in Pediatric
371	Patients with Cholelithiasis-A Preliminary Study. Journal of Clinical Medicine 11, 5613.
372	https://doi.org/10.3390/jcm11195613.
373	
374	Zdanowicz, K., Daniluk, J., Lebensztejn, D.M. & Daniluk, U. (2022) The Etiology of
375	Cholelithiasis in Children and Adolescents-A Literature Review. International Journal of
376	Molecular Sciences 23, 13376. https://doi.org/10.3390/ijms232113376.
377	
378	Zhang, Y.P., Zhao, Y.L., Sun, Y.L., Zhu, R.T., Wang, W.J. & Li, J. (2017) Physical activity
379	and the risk of gallstone disease: a systematic review and meta-analysis. Journal of Clinical

- 380 Gastroenterology 51, 857-68. <u>https://doi.org/10.1097/MCG.000000000000571</u>.
- 381
- 382 Zuo, S., Sawai, T., Kanehiro, H., Kuroda, Y. & Sho, M. (2022) Gallstones in patients with
- 383 severe motor and intellectual disability. Pediatrics International 64, e15220.
- 384 <u>https://doi.org/10.1111/ped.15220</u>.

Parameter	Group CL	Group N	р			
Number of patients	23	61	-			
Male sex	19 (82.6%)	37 (60.7%/)	.07			
Age (years, mean \pm SD)	43.6 ± 15.6	42.6 ± 15.8	.8			
Weight (kg, mean ± SD)	39.5 ± 8.0	36.8 ± 9.4	.2			
Height (cm, mean ± SD)	153.8 ± 12.5	149.6 ± 15.5	.25			
Body mass index $(kg/m^2 mean \pm SD)$	16.7 ± 2.7	16.41 ± 3.8	.75			
Diagnosed causes of SPIMD						
Neuromuscular diseases	13 (48.1%)	20 (32.8%)	.078			
Infection	1 (4.3%)	6 (9.8%)	.668			
Hypoxia encephalopathy	6 (22.2%)	8 (13.1%)	.19			
Cerebral palsy	6 (22.2%)	17 (28.9%)	1.0			
Chromosomal abnormality	0 (0%)	7 (11.5%)	.18			
GMFCS scores						
Level 1	0 (0%)	0 (0%)	.231			
Level 2	0 (0%)	1 (1.6%)				
Level 3	1 (4.3%)	11 (18.0%)				
Level 4	4 (17.4%)	15 (24.6%)				
Level 5	18 (78.3%)	34 (55.7%)				
Epilepsy	20 (87.0%)	52 (85.3%)	1.0			
Minimal communication skills	13 (56.5%)	44 (72.1%)	.2			
Cardiac disease	0 (0%)	1 (1.6 %)	1.0			
Diabetes	1 (9.1%)	1 (6.7%)	1.0			
Bladder stones	2 (8.7%)	3 (4.9%)	.6			
Urinary stones	5 (21.7%)	11 (18%)	.758			
Tracheostomy/LTS	10(43.5%)	11(18%)	.024			
Ventilator support	10 (43.5%)	9 (14.3%)	<.001			
Constipation	18 (78.3%)	49 (80.3%)	1.0			
Gastrostomy	13(56.5%)	27(44.3%)	.34			
Fundoplication	5 (21.7%)	15 (24.6%)	1.0			
Oral intake	11 (47.8%)	41 (67.2%)	.13			
Enteral nutrition	9 (39.1%)	4 (6.5%)	<.001			
TCI/W (mean \pm SD)	28.8 ± 7.59	33.0 ± 10.9	.096			
TWI/W (mean \pm SD)	33.4 ± 15.7	31.1 ± 13.3	.49			

LTS, history of laryngotracheal separation; SPIMD, severe or profound motor and intellectual disabilities; TCI/W, total calorie intake/weight; TWI/W, total water intake/weight.

X 7 • 11	Univariate analysis		Multivariate analysis	
Variables	OR (95% CI)	P value	Adjusted OR (95% CI)	P value
Male sex	3.08 (0.93-10.2)	.06		
Age (>40 years)	0.75 (0.25–2.13)	.64		
GMFCS (4–5)	0.19 (0.004–1.42)	.10		
Epilepsy	1.15 (0.25–7.23)	1.00		
Minimal communication skill	0.51 (0.17–1.55)	.20		
Oral intake	0.45 (0.17–1.19)	.11		
Gastrostomy	1.64 (0.62–4.31)	.32		
Tracheostomy/LTS	3.50 (1.22–10.0)	.02*	0.16 (0.014–1.82)	.14
Enteral nutrition	12.4 (2.97–52.0)	$<.01^{\dagger}$	10.4 (1.98–54.7)	<.01 [†]
Bladder stones	1.26 (0.39-4.14)	.70		
Urinary stones	1.60 (0.37-6.19)	.52		
Ventilator support	7.51 (2.53–22.3)	$<.01^{\dagger}$	20.0 (1.99–201.0)	.011*
Constipation	0.93 (0.26–3.84)	1.00		

 Table 2. Logistic regression of cholelithiasis prevalence in patients with SPMID.

*P < .05, $^{\dagger}P < .01$. GMFCS, Gross Motor Function Classification System; LTS, laryngotracheal separation; SPMID: severe or profound motor and intellectual disabilities.